J&J Sees Surge in MedTech Sales Post-Kenvue Split

Six months after parting ways with its consumer health unit, Kenvue, Johnson & Johnson has reported total sales of $21.4 billion for the last quarter of 2023, a 7.3% increase from the corresponding quarter in 2022. The pharmaceutical giant disclosed a net income of $4.13 billion, a rise from the $3.23 billion reported in the previous year. During their most recent quarterly earnings call on Tuesday (Jan. 23), J&J executives said the earnings growth in the first half of the year would be positively influence ...